Jubilant Biosys, a subsidiary of Jubilant Organosys, has developed a next generation screening solution, a software branded as Legend NGSS, to acceperate drug discovery programme.
The software, to be launched in the US and Europe initially, will allow scientists to capture, store, and analyze Oracle 9i/10g based screening data with greater flexibility, accuracy and speed, a company release said.
Legend NGSS allows users to create rich visualization and interactive analysis reports, including dose-response curves and scatter plot heat maps.
The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimized on-the fly curve-fitting techniques.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
